Herbst AL - Search Results

1

Comparison of short-lived high-LET alpha-emitting radionuclides lead-212 and bismuth-212 to low-LET X-rays on ovarian carcinoma.

Rotmensch J, Atcher RW, Hines J, Toohill M, Herbst AL. Rotmensch J, et al. Among authors: herbst al. Gynecol Oncol. 1989 Dec;35(3):297-300. doi: 10.1016/0090-8258(89)90067-x. Gynecol Oncol. 1989. PMID: 2599463

2

The development of alpha-emitting radionuclide lead 212 for the potential treatment of ovarian carcinoma.

Rotmensch J, Atcher RW, Hines J, Grdina D, Schwartz JS, Toohill M, Herbst AL. Rotmensch J, et al. Among authors: herbst al. Am J Obstet Gynecol. 1989 Apr;160(4):789-97. doi: 10.1016/0002-9378(89)90293-7. Am J Obstet Gynecol. 1989. PMID: 2712112

3

The effect of the alpha-emitting radionuclide lead-212 on human ovarian carcinoma: a potential new form of therapy.

Rotmensch J, Atcher RW, Schlenker R, Hines J, Grdina D, Block BS, Press MF, Herbst AL, Weichselbaum RR. Rotmensch J, et al. Among authors: herbst al. Gynecol Oncol. 1989 Feb;32(2):236-9. doi: 10.1016/s0090-8258(89)80040-x. Gynecol Oncol. 1989. PMID: 2910786

4

Evaluation of bolus cis-platinum and continuous 5-fluorouracil infusion for metastatic and recurrent squamous cell carcinoma of the cervix.

Rotmensch J, Senekjian EK, Javaheri G, Herbst AL. Rotmensch J, et al. Among authors: herbst al. Gynecol Oncol. 1988 Jan;29(1):76-81. doi: 10.1016/0090-8258(88)90149-7. Gynecol Oncol. 1988. PMID: 3338666

5

Estimates of dose to intraperitoneal micrometastases from alpha and beta emitters in radioimmunotherapy.

Rotmensch J, Roeske J, Chen G, Pelizzari C, Montag A, Weichselbaum R, Herbst AL. Rotmensch J, et al. Among authors: herbst al. Gynecol Oncol. 1990 Sep;38(3):478-85. doi: 10.1016/0090-8258(90)90095-3. Gynecol Oncol. 1990. PMID: 2227565

6

Preoperative radiotherapy followed by radical vulvectomy with inguinal lymphadenectomy for advanced vulvar carcinomas.

Rotmensch J, Rubin SJ, Sutton HG, Javaheri G, Halpern HJ, Schwartz JL, Stewart M, Weichselbaum RR, Herbst AL. Rotmensch J, et al. Among authors: herbst al. Gynecol Oncol. 1990 Feb;36(2):181-4. doi: 10.1016/0090-8258(90)90169-l. Gynecol Oncol. 1990. PMID: 2298406

7

Influence of in utero diethylstilbestrol exposure on the prognosis and biologic behavior of vaginal clear-cell adenocarcinoma.

Waggoner SE, Mittendorf R, Biney N, Anderson D, Herbst AL. Waggoner SE, et al. Among authors: herbst al. Gynecol Oncol. 1994 Nov;55(2):238-44. doi: 10.1006/gyno.1994.1284. Gynecol Oncol. 1994. PMID: 7959291

8

Pelvic exenteration in clear cell adenocarcinoma of the vagina and cervix.

Senekjian EK, Frey K, Herbst AL. Senekjian EK, et al. Among authors: herbst al. Gynecol Oncol. 1989 Sep;34(3):413-6. doi: 10.1016/0090-8258(89)90183-2. Gynecol Oncol. 1989. PMID: 2767532

9

An evaluation of stage II vaginal clear cell adenocarcinoma according to substages.

Senekjian EK, Frey KW, Stone C, Herbst AL. Senekjian EK, et al. Among authors: herbst al. Gynecol Oncol. 1988 Sep;31(1):56-64. doi: 10.1016/0090-8258(88)90269-7. Gynecol Oncol. 1988. PMID: 3410356

10

Behavior of estrogen-associated female genital tract cancer and its relation to neoplasia following intrauterine exposure to diethylstilbestrol (DES).

Herbst AL. Herbst AL. Gynecol Oncol. 2000 Feb;76(2):147-56. doi: 10.1006/gyno.1999.5471. Gynecol Oncol. 2000. PMID: 10637063 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

161 results

Search Page

Filters